Addex therapeutics to release full-year 2023 financial results and host conference call on april 18, 2024

Geneva, switzerland, april 11, 2024 – addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, today announced that it will issue its full-year 2023 financial results on april 18, 2024. tim dyer, ceo and mikhail kalinichev, head of translational science will provide a business update and a review of the addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 cest (15:00 bst / 10:00 edt / 07:00 pdt) the same day.
ADXN Ratings Summary
ADXN Quant Ranking